Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/10/2024 | $30.00 | Buy | H.C. Wainwright |
4/2/2024 | $30.00 | Buy | Goldman |
3/7/2023 | Outperform | Evercore ISI | |
3/7/2023 | $39.00 | Buy | BofA Securities |
3/7/2023 | $32.00 | Buy | Guggenheim |
3/7/2023 | $27.00 | Overweight | Wells Fargo |
3/7/2023 | $45.00 | Buy | Stifel |
3/7/2023 | $40.00 | Outperform | Credit Suisse |
4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
– Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025 – – Enrollment ahead of schedule in Phase 3 pivotal Launch-HTN trial and on track to deliver topline data as anticipated in 2H 2025 – – Ongoing Explore-CKD Phase 2 trial is ramping up enrollment under the amended protocol and is anticipated to deliver topline data in 1H 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldost
RADNOR, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2024, after the financial markets close on Tuesday, August 13, 2024. Tuesday, August 13th @ 4:30 p.m. ETDomestic:1-877-407-9127International:1-201-689-8574Webcast:Link A live webcast of the conference call may be found here or on the "News & Events" page in the Investor Relations section of the Mineralys Therapeutics websi
– Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in Q4 2024 – – Ongoing Phase 3 pivotal Launch-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in 2H 2025 – – Ongoing Explore-CKD Phase 2 trial is anticipated to deliver topline data in Q4 2024 to Q1 2025 – – Conference call today at 8:30 a.m. ET – RADNOR, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announ
8-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)
144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $30.
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.67) by 4.48 percent. This is a 37.25 percent decrease over losses of $(0.51) per share from the same period last year.
– Topline data now anticipated in mid first half of 2025 – – Management to host virtual KOL event today to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hypertension – RADNOR, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular diseases driven by dysregulated aldosterone, today announced that it has completed enrollment in the Launch-HTN trial ahead of schedule. Launch-HTN is the second of two trials under the planned pivota
RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular diseases driven by dysregulated aldosterone, today announced full details for its upcoming virtual KOL event being held on Wednesday, October 30, 2024, at 10:00 AM ET. To register for the event, please click here. The event will feature comments from Luke J. Laffin, MD (Cleveland Clinic), James M. Luther, MD, MSCI (Vanderbilt University Medical Center), and Rhian Touyz, MBBCh, MSc (Med), PhD (McGill University Health Centre) who will each
– On track to announce topline data in Q1 2025 – – Virtual KOL event scheduled on October 30th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hypertension – RADNOR, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular diseases driven by dysregulated aldosterone, today announced that it has achieved the enrollment target of 261 subjects in the pivotal Advance-HTN trial evaluating the efficacy and safety of lorundrostat
H.C. Wainwright initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00
Goldman initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00
Evercore ISI initiated coverage of Mineralys Therapeutics with a rating of Outperform
RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointment of Minji Kim, Ph.D. as Chief Business Officer. Adam Levy will remain in his role as Chief Financial Officer. "With our expanding operations, we have decided to split the functions of Chief Financial Officer and Chief Business Officer into two roles, and we are excited to have Minji join our team. She brings a solid track record of generating value for multiple companies by identify
LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch ("Praxis"), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and neurodegenerative disorders with an initial focus on apathy in Alzheimer's Disease, today announced the appointment of Adam Levy to its Board of Directors (the "Board"). Mr. Levy brings executive, financial and operational leadership experience in biopharmaceuticals. "We are excited to have Adam join our Board and support our mission to improve the lives of patients with Alzheimer's Disease," said Sandeep Patil, MD PhD, chief executive officer of Praxis Bioresearch. "Adam brings an impressive